Exhibition Hall 1, Level 1, BICC
| A01 | Shanghai
Roche Pharmaceuticals Co., Ltd | | A02 | Beijing Novartis Pharma Ltd. | | A03 | Sino-American Shanghai Squibb Pharmaceuticals Ltd. | | A04 | Shangdong ShiBo JinDu Pharmaceutical Co., Ltd | | A05 | MSD | | A06 | GlaxoSmithKline (China) Investment Co., Ltd | | B01 - 02 | Pearl Ocean Pharmaceutical Holdings Limited | | B03 - 04 | Abbott | | B05 | Eisai China Pharmaceutical Inc. | | B06 - 07 | Beijing Union Pharmaceutical Factory | | C01 - 02 | Fujian Cosunter Pharmaceutical Co., Ltd. | | C03 | Sanofi-aventis China | | C04 | (reserved) | | C05 - 06 | Coland Pharmaceutical Co., Ltd | | C07 | Sunlon Pharmaceutical | | C08 | Make Biomedical Wuxi
Inc. | | C09 | (reserved) |
Exhibitors Profiles
| Shanghai
Roche Pharmaceutical Co., Ltd | A01 | | | 1100 Long Dong Ave., Shanghai 201203, P.R. China | | | | | Roche group is based in Basel, Switzerland, in pharmaceuticals
and diagnostics is the world’s leading research-based, innovation-driven healthcare companies. Set up branches in Hong
Kong in 1961, 1984, Rose back to mainland China market, and in 1994 established the first China joint venture – Shanghai
Roche Pharmaceutical Co., Ltd. The total investment amounts to 45 million U.S. dollars, to provide tumor, virology, transplantation
science and other kinds of key therapeutic areas of breakthrough drugs, efforts to radically improve the quality of life.
September 1, 2009, the Asia-Pacific regional headquarters Roche settled in Shanghai Roche drug development center in China
for Roche pharmaceutical clinical research and development to upgrade the Asia-Pacific Center | | | | | | Beijing Novartis Pharma Ltd. | A02 | | | 14/F, China World Tower 2, No. 1 Jian Guo
Men Wai Avenue, Beijing 100004, P.R. China | | | | | Novartis is a world leader in offering medicines to protect health, cure diseases and improve well being.The name Novartis is derived from the Latin novae arts, which means “new skills”,
and reflects our commitment to developing innovative healthcare solutions to meet the evolving needs of patients and societies
worldwide.Novartis is positioned to lead in innovation, partner
with others and offer solutions to patients across a broad healthcare spectrum. | | | | | | Sino-American Shanghai Squibb Pharmaceuticals
Ltd. | A03 | | | 6/F.,
Fu Xing Plaza, 109 Yan Dang Road, Shanghai, P.R. China | | | | | Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative
medicines that help patients prevail over serious diseases.The
company is a leader in such disease areas as cancer, cardiovascular diseases, metabolic disorders, HIV/AIDs and infectious
diseases. By uniquely combining the reach and resources of a major pharmaceutical company with the agility and entrepreneurial
spirit of an innovative biotech company, BMS is transforming into a next-generation BioPharma leader. BMS has three legal entities in China. They are: Bristol-Myers Squibb (China) Investment Co.,
Ltd., Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd., and Bristol-Myers Squibb (Shanghai) Trading Co., Ltd. The Sino-American Shanghai Squibb Pharmaceuticals
Co., Ltd. (SASS) is the first Sino-American pharmaceutical joint venture in China, which was established on October 14th,
1982 and officially started operation in October 1985. SASS is invested by BMS, Shanghai Corporation of Medicines (Group)
and China National Pharmaceutical Foreign Trade Corporation. SASS’ manufacturing facility is located in the Shanghai
Minhang High-tech Technology Park, with a floor area of about 55000 square meters. SASS is a leading player in China’s pharmaceutical
industry. In 1985, the company established the first professional sales team in the industry and then achieved the quality
and export certification from Canada, New Zealand and the United States. SASS is also the first pharmaceutical enterprise
to achieve the national GMP certification in Shanghai. In 2001, SASS achieved the national GMP certification for its entire
production lines. | | | | | | Shandong ShiBo JinDu Pharmaceutical Co., Ltd. | A04 | | | 12th
Floor, Wanbo Mall, No. 72 Youanmennei, Xuanwu District, Beijing, China | | | | | Shibojindu (SBJD) pharmaceutical company is a modern high-tech oriented joint-stock enterprise.
It takes research, development and production of traditional Chinese & western medicine and health care products as a
leader, and set Trade and Industry as a whole. Through more than 40 years clinical verification supported by hundreds of thousands
of patients, it demonstrated that Liuwei Wuling tablet exclusively produced by SBJD, a national new drug for hepatic disease,
has a remarkable effect on protecting liver, decreasing the activity of transaminase, blocking hepatic fibrosis and treating
liver injury. | | | | | | MSD | A05 | | | 20/F.,
Park Place, 1601 Nanjing Road (West), Shanghai 200020, P.R. China | | | | MSD (known as Merck & Co., Inc. in America) is a leading global healthcare company, providing
innovative drugs, vaccines, biotherapy and consumer and animal health products. In partnership with our clients, we offer
a wide range of healthcare solutions in over 140 countries and regions. We are committed to expanding the availability of
drugs through various projects of far-reaching significance; not only donating MSD-produced drugs, but helping people in need
obtain drugs. We are also engaged in the non-profit publication of fair and independent medical information.For more details, please visit the MSD company website: www.msd.com and www.msdchina.com.cn. ·
Company headquarters are located in Whitehouse Station, New
Jersey, USA · Approximately 100,000 employees worldwide · 2009 annual revenue of $27.4 billion ·
2009 R&D expenditure of $5.8 billion | | | | | | GlaxoSmithKline (China) Investment Co., Ltd. | A06 | | | 5/F, The Headquarters Building, No. 168
Tibet Road (M), Shanghai 200001, China | | | | | GlaxoSmithKline (China) Investment Co., Ltd. was officially established in 2001. GSK (China) is one of the
largest multinational pharmaceutical companies in China. GSK (China) are providing a wide range of innovation products to
China market, including medicines for hepatitis, diabetes, AIDs, depression, oncology, cardio-vascular etc. Total R&D
investment in China has been over RMB 1 billion, GSK have collaborated with over 30 leading medical universities/hospitals
in the fields of hepatitis B, type II diabetes, etc. | | | | | | Pearl Ocean Pharmaceutical Holdings
Limited | B01-02 | | | Room
1008, North Building, New World Center, No. 3B, Chong Wen Men Wai Street, Beijing, P.R. China | | | | | Qingdao Pearl Ocean Pharmaceutical Inc. (QBY) is a subsidiary
of the holding company registered in Hong Kong. With net Sales USD$70MM in 2007, two major products selling combined $44MM.
QBY has 45 offices nationwide, More than 800 sales force, 4000 hospitals covered and 500 distribution partners. QBY owned
many industry awards including Fastest Growing Pharmaceutical Company in 2006 and China Companies IT 500, China Red Cross
Humanitarian Service Awards, China Physician Moral and Legal Assistance Fund, the 2008 Pharmaceutical Brand Board. | | | | | | Pearl Ocean Pharmaceutical Holdings Limited | B01-02 | | | Room 1008, North Building, New World Center,
No. 3B, Chong Wen Men Wai Street, Beijing, P.R. China | | | | | Qingdao Pearl Ocean Pharmaceutical Inc. (QBY) is a subsidiary of the holding company registered in Hong Kong.
With net Sales USD$70MM in 2007, two major products selling combined $44MM. QBY has 45 offices nationwide, More than 800 sales
force, 4000 hospitals covered and 500 distribution partners. QBY owned many industry awards including Fastest Growing Pharmaceutical
Company in 2006 and China Companies IT 500, China Red Cross Humanitarian Service Awards, China Physician Moral and Legal Assistance
Fund, the 2008 Pharmaceutical Brand Board. | | | | | | Abbott | B03-04 | | | 32/F., Ciro’s Plaza, 388 Nanjing
West Road, Shanghai 200003, China | | | | | Abbott is a global, broad-based healthcare company devoted to the discovery, development, manufacture and marketing
of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. Global citizenship is an integral
part of Abbott’s mission to improve people’s lives. Responsible citizenship is critical to Abbott’s long-term
competitiveness, and is reflected in how it conducts business around the world, protects the environment and builds healthier
communities. For more information, please visit www.abbott.com/citizenship. | | | | | | Eisai China Pharmaceutical Inc. | B05 | | | 39th
Floor, Park Plaace, No. 1601 Nanjing Xi Road, Shanghai, P.R. China | | | | | Eisai China Inc. is a pharmaceutical company solely invested by Eisai Co., Ltd. Japan, a multinational
pharmaceutical company with strong R&D capabilities. It was founded in 1941. With the headquarter located in Tokyo. Since
its foundation, the company has actively expanded into overseas markets and now has sales subsidiaries and factories in America,
Europe and Asia. | | | | | | Beijing Union Pharmaceutical Factory | B06-07 | | | Xingye Beilu, Huangcun, Daxing District,
Beijing, P.R. China | | | | | Beijing Union Pharmaceutical Factory was founded in 1958 and is subordinate to institute of Meteria Medica.
With the enterprise aim of “surviving by good quality, developing by progress in science and marking a contribution
to improving human’s health”, it has developed from an experimental base for new medicine to a pharmaceutical
enterprise capable of producing, developing and selling medicine. New it is staffed with 370 people. Since 2002, it has been
listed as “the new and high technical enterprise”. The “Union” brand has won a good reputation in
the national pharmaceutical industry for its creation and good quality. | | | | | | Fujian Cosunter Pharmaceutical Co., Ltd. | C01-02 | | | 32nd Floor, Global Square, No.
158, Wusi Road, Fuzhou, Fujian, P.R. China | | | | | COSUNTER Pharmaceutical Company is a pharmaceutical group engaging in medical research and development, production
and sale. COSUNTER Pharmaceutical Company is awarded the title of one of top 100s of Chinese potential in Forbes rank-board
and top 500s with the most competitive enterprises and well-known trademark in Fujian in 2005. | | | | | | Sanofi-aventis China | C03 | | | 7/F.,
No. 112, Jian Guo Lu, Chaoyang District, Beijing 100022, P.R. China | | | | | Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic
solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
For more information, visit www.sanofi-aventis.com. | | | | | | Coland Pharmaceutical Co., Ltd | C05-06 | | | Room 103, No. 866 Halei Road, Zhangjiang
High Technology Park, PuDong District, Shanghai 201203, China | | | | | Coland is a specialty pharmaceutical company focusing on marketing branded products and developing solid pipelines
through collaboration with leading institutes. Our main interests are in the dedicated therapeutic areas – Hepatitis,
Immunology, Oncology, and other niche areas. Coland was started
its sales operation in 2005. Daiding TM (Adefovir), a first-to-market generic, that treats HBV was launched in
2005. With effective promotion, and brand building, Daiding achieved great success and gained the leading position in China.Our goal is to become a leading specialty pharmaceutical company in China with strong sales
and marketing capabilities and solid product pipelines. | | | | | | Sunlon Pharmaceutical | C07 | | | Jingdong Yanjiao Economic Technology Development
Zone, Beijing, China | | | | | Sunlon Pharmaceutical Co., Ltd., with a registered capital of RMB 30 million and a total investment of RMB
60 million, is a new and modernized enterprise of Chinese medicine that integrates R&D, production, medical care and sale.
Located in the Industrial Park of Medicine in the Yanjiao Economy and Technology Development Zone in Beijing, the company
occupies an area of 100 mu and possesses a modernized factory premise of 7,000M2, which is designed and constructed
completely according to the GMP standard, and is equipped with the top grade facilities. | | | | | | Make Biomedical Wuxi Inc. | C08 | | | 1619 Huishan Avenue, Wuxi P.R. China | | | | | Make Biomedical Wuxi Inc. is founded by American doctor Jianguo
Tao’s technological team and Jinhui Venture Investment Wuxi Inc., that registered capital is 6,000,000 Yuan. It is estimated
that the first phase investment to construct GMP workshop is 10,000,000 Yuan, which include three independent production lines
of PCR kits, ELISA kits and colloidal gold immunoassay kits. It enjoy in research, production and sale and is a high and new
technology enterprise. The products declared and preparation to declare covered most main diagnosis methods of PCR kits, ELISA
kits and colloidal gold immunoassay kits. After the construction, the enterprise will through the GMP authentication, and
has first-class production equipments. With the talented persons including management, research and development, quality control,
production and marketing, we will form strictly comprehensive quality control system and consummation organizations and agencies,
and will set up humanist management idea, pursue high quality and effective service content, which will lay solid foundation
for enterprise's continually development. High quality is realized by mature, stable production technical process and consummation
quality examination management system. | | | | | | | | |
|
|
|
